First Ascent Biomedical's Chief Science Officer, Dr. Diana Azzam, is currently running a 2-year clinical trial in partnership with Florida International University and the Cleveland Clinic Florida.
The trial focuses on adults with recurrent sarcoma who have already had 2 rounds or cycles of treatment. The study is observational comparing standard of care to suggested precision therapies.
Enrollment is open until December 2022 or before as enrollment quota is reached.
Read about the introduction of the trial here.